Trials in Florida.
188 APOE4-relevant Alzheimer’s trials run in Florida — 92 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Where
- Miami · Tampa · Orlando · Maitland · Hialeah · The Villages · Delray Beach · Atlantis
- Recruiting
- 92 of 188
Non-carriers only, not for APOE4
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
CompletedPhase 3NCT00574132Drug trial for diagnosed APOE4 carriers
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
CompletedPhase 3NCT00575055Stratified by APOE4 genotype specifically
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)This trial tests AC-1204, an oral ketogenic compound made from caprylic triglyceride, in people with mild to moderate Alzheimer's disease. The idea is that…
WithdrawnPhase 2NCT01211782Carriers enrolled, but higher ARIA risk
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseThis Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
CompletedPhase 2NCT01767311Built exclusively for APOE 4/4 carriers
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseThis trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
TerminatedPhase 2NCT02565511Built specifically for APOE4 carriers
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseThis trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
TerminatedPhase 2NCT03131453Built exclusively for APOE4 homozygotes
Gene Therapy for APOE4 Homozygote of Alzheimer's DiseaseThis Phase 1 trial is testing LX1001, a gene therapy delivered into the spinal fluid, in people who carry two copies of APOE4 and already have…
CompletedPhase 1NCT03634007Excludes APOE4 homozygotes (4/4 carriers)
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's DiseaseThis study tests whether a focused-ultrasound device, guided by MRI, can safely and temporarily open the blood-brain barrier in people with probable…
RecruitingObservationalNCT03671889Open to carriers, but ARIA risk elevated
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseThis Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
ActivePhase 3NCT03887455Exclusively enrolls APOE4 homozygotes
Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease ProgressionThis trial is testing whether it is safe to give plasma from young APOE3 carriers to people who are APOE4 homozygous and already showing mild cognitive…
CompletedPhase 1NCT03887741APOE4 carriers explicitly welcomed
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidThis Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
ActivePhase 3NCT04468659Built exclusively for APOE4/4 carriers
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD SubjectsThis Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
CompletedPhase 3NCT04770220APOE4/4 specific, prior participants only
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's DiseaseThis study follows people who already received LX1001, an experimental gene therapy that delivers a protective APOE2 gene into the brain. It mainly checks…
ActivePhase 1NCT05400330Explicitly welcomes APOE4 carriers
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid PathologyThis is a screening study, not a treatment trial. Researchers are using blood tests to find people who may have high levels of amyloid protein in the brain — a…
ActiveNCT06043700APOE4/4 only, closed to new enrollees
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD SubjectsThis is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
TerminatedPhase 3NCT06304883Drug trial for symptomatic early Alzheimer's
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…
ActivePhase 2NCT06335173Device study for diagnosed patients, not 4-specific
Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological DiseasesThis pilot study asks people with neurological diseases, and their caregivers, how it feels to use the MemorEM, a head-worn device, over a long period. The…
Invitation onlyObservationalNCT07049341Open to carriers, not 4-specific
IMST for Dementia Risk ReductionThis trial tests whether a simple breathing-muscle workout, done at home for about 5 to 10 minutes a day over 8 weeks, can improve blood pressure, thinking,…
RecruitingObservationalNCT073497064/4 carriers excluded, one copy may qualify
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's DiseaseThis Phase 2 trial is testing SAR448851, a once-daily oral pill, in people with early Alzheimer's disease who have confirmed amyloid buildup in the brain.…
RecruitingPhase 2NCT07688213ALS family study, unrelated to APOE4
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) StudyThis is an observational study, not a drug test. Researchers follow healthy people from families with inherited ALS (Lou Gehrig's disease) over time. They use…
RecruitingNCT00317616APOE4 enrolled, response may differ
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's DiseaseThis Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
CompletedPhase 3NCT00348140Enrolled carriers, prior data unfavorable
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's DiseaseThis trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
CompletedObservationalNCT00348309APOE4 stratified, suggests less benefit
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's DiseaseThis Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
CompletedPhase 3NCT00428090Closed trial, APOE4 stratified
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate AlzheimersThis Phase 3 trial tested rosiglitazone XR, a diabetes drug, in people with mild-to-moderate Alzheimer's disease. It was an open-label extension study, meaning…
TerminatedPhase 3NCT00550420Drug trial, genotype not specified in source
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease PatientsThis trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…
TerminatedPhase 3NCT00667810Drug trial, not APOE4-specific, carriers at risk
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease PatientsThis trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…
TerminatedPhase 3NCT00676143Open to carriers, not 4-specific
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's DiseaseThis trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…
CompletedPhase 2NCT00710684Rare inherited mutation families, not APOE4
Dominantly Inherited Alzheimer Network (DIAN)This is an observational study, meaning no drug or treatment is given. Researchers follow families with a rare inherited gene mutation that causes Alzheimer's,…
RecruitingNCT00869817Drug extension study, prior participants only
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease PatientsThis trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…
TerminatedPhase 3NCT00998764Cancer trial, not for healthy carriers
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain MetastasesThis trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…
CompletedPhase 2NCT01227954Huntington's study, not about APOE4
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease CohortEnroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…
RecruitingNCT01574053Amyloid-focused, drug did not succeed
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossThis Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
CompletedPhase 3NCT02008357Open to carriers, not 4-specific
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's DiseaseThis trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
TerminatedPhase 2NCT02245737Not Alzheimer's-focused, not APOE4-specific
Phenotype, Genotype & Biomarkers in ALS and Related DisordersThis is an observational study, so nothing is being tested as a treatment. Researchers are looking at how the genes and symptoms of ALS and related conditions,…
ActiveNCT02327845Lymphoma study, not Alzheimer's-related
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin LymphomasThis study looks at whether a blood test can spot aggressive B-cell lymphoma coming back after first-round chemotherapy. The test reads tumor DNA left in the…
ActiveNCT02633111Not APOE4-specific; for existing neurologic damage
Neurologic Stem Cell Treatment StudyThis study takes a person's own bone marrow stem cells and delivers them through a vein and the lower nose. Researchers want to see whether neurologic function…
RecruitingObservationalNCT02795052Heart trial, genotype not relevant
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection FractionThis Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
CompletedPhase 3NCT02884206Observational only, no treatment involved
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
ActiveNCT02951598Discontinued trial, not APOE4-specific
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease DementiaThis Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
TerminatedPhase 3NCT02972658Open to carriers, not 4-specific
Escitalopram for Agitation in Alzheimer's DiseaseThis Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
ActivePhase 3NCT03108846Genotype-blind, not APOE4-specific
Clinical Applications of Advanced Ophthalmic ImagingThis study is testing whether advanced eye-imaging tools — including OCT scans and retinal imaging — can detect changes in the eyes of people with conditions…
RecruitingObservationalNCT03135327Not relevant: ALS records study, no APOE4
Clinical Procedures to Support Research in ALSThis study uses information already in the medical records of people with ALS and related conditions to learn more about those diseases. It tests no drug or…
RecruitingNCT03489278Open to carriers, not 4-specific
Longitudinal Early-onset Alzheimer's Disease Study ProtocolLEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
ActiveNCT03507257Open to carriers, not 4-specific
Multi-Center Study of Sensory Stimulation to Improve Brain FunctionThis trial tests a device called the GammaSense Stimulation System, which delivers sensory stimulation at a specific brain rhythm frequency called gamma.…
ActiveObservationalNCT03556280Open to carriers, not 4-specific
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer'sThe LUCINDA Trial is testing whether leuprolide acetate, a hormone-suppressing drug already used for other conditions, can slow cognitive decline when added to…
CompletedPhase 2NCT03649724Open to carriers, not 4-specific
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive TherapyThis trial is testing an iPad app called AlzLife that flashes light at 40 times per second (40Hz) combined with cognitive exercises. The idea is that this…
RecruitingNCT03657745No relevance to APOE4 carriers
Myelin Imaging in Concussed High School Football PlayersThis study uses a specialized MRI technique called McDESPOT to look at myelin — the protective coating around nerve fibers in the brain — in high school…
TerminatedNCT03698747Women 60+, APOE4 not mentioned
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's DiseaseThis study looks at whether a woman's ovarian hormones are linked to how the brain ages and to Alzheimer's risk. Participants get a brain scan using…
RecruitingPhase 4NCT03821857Open to carriers, not 4-specific
Preventing Alzheimer's With Cognitive TrainingThis Phase 3 trial is testing whether a specific type of computerized brain training — called speed of processing training — can delay the onset of mild…
ActivePhase 3NCT03848312Not Alzheimer's-focused, not APOE4-specific
TRIAL READY (Clinical Trial Readiness)This is an observational study, not a drug test. It collects biological fluid samples, such as blood, from people with ALS and related conditions, plus healthy…
ActiveNCT03912987
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.